Chief Medical Officer, Kailera Therapeutics: Oral ribupatide shows a potentially game-changing clinical profile Kailera Therapeutics plans to initiate another Phase 2 oral study this year Chief of Clinical Development, Metabolic Diseases, Hengrui Pharma confirmed plans to advance into Phase 3 in China 5 Oral + injectable = portfolio hedge Kaileras lead injectable ribupatide (KAI-9531) already showed: 19.2% mean weight loss at 36 weeks (Phase 3, China) Comparable to @Eli Lilly and Companys Zepbound Oral ribupatide now adds access, convenience, and lifecycle flexibility
Theyre also generally well tolerated with reflux
Another compounded injectable product reportedly contained 86.2% peptide related impurities, including roughly 29% tirzepatide and tirzepatide related impurities, despite being labeled as semaglutide
Large cardiovascular outcome trials involving over 60,000 patients found no statistically significant increase in pancreatitis rates with GLP-1 agonists versus placebo
As for the thyroid cancer warning you may have heard about, that comes from studies in rodents
So, its a, its an individualized prescription, and they walk out, and then theyre likely to see someone they know
